NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential ...

NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

GSK PLC closed 26.98% short of its 52-week high of £18.24, which the company reached on May 16th.

GSK PLC closed 30.68% below its 52-week high of £18.24, which the company achieved on May 16th.

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

Drugmakers' stocks in Europe and India dropped on Wednesday after U.S. President Donald Trump reiterated plans for a "major" ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

Drugmakers' stocks in Europe and India slipped on Wednesday after U.S. President Donald Trump reiterated plans for a "major" ...

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...